STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY

被引:119
作者
Button, Michael R. [4 ]
Morgan, Carys A. [1 ]
Croydon, Elizabeth S. [2 ]
Roberts, S. Ashley [3 ]
Crosby, Thomas D. L. [4 ]
机构
[1] Bristol Oncol Ctr, Dept Clin Oncol, Bristol, Avon, England
[2] Chase Farm Hosp, Enfield, Middx, England
[3] Univ Wales Hosp, Dept Radiol, Cardiff CF4 4XW, S Glam, Wales
[4] Velindre Oncol Ctr, Dept Clin Oncol, Cardiff, S Glam, Wales
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 73卷 / 03期
关键词
Esophageal cancer; Chemoradiotherapy; Relapse patterns; Radiotherapy margins; POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; NEOADJUVANT CHEMORADIOTHERAPY; CHEMOTHERAPY; CANCER; CHEMORADIATION; SURGERY; RADIATION; CETUXIMAB; TRIAL;
D O I
10.1016/j.ijrobp.2008.04.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To ascertain the adequacy of radiotherapy (RT) margins by studying the relapse patterns after definitive chemoradiotherapy for carcinoma of the esophagus. Methods and Materials: We performed a retrospective study assessing the first site of disease relapse after definitive chemoradiotherapy that included four 3-weekly cycles of cisplatin and continuous infusion 5-fluorouracil, with conformal RT (50 Gy in 25 fractions) concurrent with Cycles 3 and 4. The RT planning target volume was the endoscopic ultrasonography/computed tomography-defined gross tumor volume with 1.5-cm lateral and 3-cm superoinferior margins. Results: A total of 145 patients were included. Their average age was 65.4 years, 45% had adenocarcinoma, 61% bad lower third esophageal tumors, and 75% had Stage III-IVA disease. After RT, of 142 patients, 85 (60%) had evidence of relapse at a median follow-up of 18 months. The relapse was local (within the RT field) in 55; distant (metastatic) in 13, and a combination of local and distant in 14. The local relapse rates were not influenced by tumor stage, lymph node status, or disease length. Three patients developed a relapse in regions adjacent to the RT fields; however, it is unlikely that larger field margins would have been clinically acceptable or effective in these cases. The median overall survival was 15 months. Conclusion: The gross tumor volume-planning target volume margins in this study appeared adequate. Future efforts to improve outcomes using definitive chemoradiotherapy should be directed toward reducing the high rates of in-field and distant relapses. (C) 2009 Elsevier Inc.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 30 条
[1]  
Bedenne L., 2002, P AM SOC CLIN ONCOL, V21, p130a
[2]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[3]  
Button MR, 2007, CLIN ONCOL-UK, V19, pS25, DOI 10.1016/j.clon.2007.01.343
[4]   Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: Mature results of phase II study [J].
Choi, NC ;
Park, SD ;
Lynch, T ;
Wright, C ;
Ancukiewicz, M ;
Wain, J ;
Donahue, D ;
Mathisen, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01) :111-122
[5]   Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[6]   Definitive chemoradiation in patients with inoperable oesophageal carcinoma [J].
Crosby, TDL ;
Brewster, AE ;
Borley, A ;
Perschky, L ;
Kehagioglou, P ;
Court, J ;
Maughan, TS .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :70-75
[7]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[8]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[9]   Relapse patterns after chemo-radiation for carcinoma of the oesophagus [J].
Denham, JW ;
Steigler, A ;
Kilmurray, J ;
Wratten, C ;
Burmeister, B ;
Lamb, DS ;
Joseph, D ;
Delaney, G ;
Christie, D ;
Jamieson, G ;
Smithers, BM ;
Ackland, S ;
Walpole, E .
CLINICAL ONCOLOGY, 2003, 15 (03) :98-108
[10]  
DENITTIS AS, 2004, PRINCIPLES PRACTICE, P1282